Introduction: Regarding to the role of the zinc in the metabolism of the central nervous system and the correlation of zinc supplementation in the treatment of any Attention deficit hyperactivity disorder (ADHD) symptoms, this study was conducted to evaluate the complementary effects of this nutrient.
Method: This was a double-blind randomized clinical trial study and 60 children with ADHD who were treated with methylphenidate were chosen by random allocation and were divided in the two groups: 30 for the case and 30 for the control group. The treatment in case group was augmented with zinc. Duration of study was six weeks.
Result: Forty eight (80%) of participants were boy and 12 (20%) were girl. The mean age of patients was 9.6 ± 1.70 years. There was no significant difference between the two groups after the intervention in terms of total score, hyperactivity and impulsivity subscales during variance analysis, but there was a significant difference between the mean of inattention score.
Conclusion: Augmentation with zinc can enhance the improvement of inattention.
Keywords: Attention deficit hyperactivity disorder; Augmentation; Connors questionnaire; Methylphenidate; Zinc.
Copyright © 2019 Elsevier B.V. All rights reserved.
Zinc Sulfate as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Double Blind and Randomized Trial [ISRCTN64132371]S Akhondzadeh et al. BMC Psychiatry 4, 9. PMID 15070418. - Clinical TrialThis double-blind, placebo-controlled study demonstrated that zinc as a supplementary medication might be beneficial in the treatment of children with attention-deficit h …
Methylphenidate for Children and Adolescents With Autism Spectrum DisorderN Sturman et al. Cochrane Database Syst Rev 11 (11), CD011144. PMID 29159857. - ReviewWe found that short-term use of methylphenidate might improve symptoms of hyperactivity and possibly inattention in children with ASD who are tolerant of the medication, …
Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults With Attention-Deficit Hyperactivity DisorderRH Weisler et al. CNS Drugs 26 (5), 421-34. PMID 22519922. - Randomized Controlled TrialBavisant, a highly selective, wakefulness-promoting H3 antagonist, did not display significant clinical effectiveness in the treatment of adults with ADHD.
Immediate-release Methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) in AdultsT Epstein et al. Cochrane Database Syst Rev (9), CD005041. PMID 25230710. - ReviewData from randomized controlled trials suggest that immediate-release methylphenidate is efficacious for treating adults with ADHD with symptoms of hyperactivity, impulsi …
Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity DisorderJH Newcorn et al. CNS Drugs 31 (11), 999-1014. PMID 28980198.LDX was superior to OROS-MPH in adolescents with ADHD in the forced-dose but not the flexible-dose study. Safety and tolerability for both medications was consistent with …